Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists

NVNO - enVVeno Medical Corporation Stock Price, Fair Value and News

$4.12-0.87 (-17.43%)
Market Closed
Max Portfolio Pct.
Check
Valuation
Check

Stock Quality:

GPSDBMFI
Max Portfolio Pct.
Check
Valuation
Check
GPSDBMFI

NVNO Price Action

Last 7 days

10.8%

Last 30 days

0.8%

Last 90 days

32.9%

Trailing 12 Months

-4.7%

NVNO Stock Price

$4.12

NVNO RSI Chart

NovDec2025FebMarAprMayJunJulAug102030405060708090100

NVNO Valuation

Market Cap

96.4M

Price/Earnings (Trailing)

-4.18

Price/Sales (Trailing)

229.05

Price/Free Cashflow

-5.18

NVNO Price/Sales (Trailing)

202220232024202501K2K3K4K5K

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

NVNO Fundamentals

NVNO Revenue

Revenue (TTM)

421.0K

Rev. Growth (Yr)

167.12%

Rev. Growth (Qtr)

107.45%

20182020202220240100K200K300K400K

NVNO Earnings

Earnings (TTM)

-23.1M

Earnings Growth (Yr)

-35.07%

Earnings Growth (Qtr)

-48.66%

2018202020222024-25M-20M-15M-10M

NVNO Profitability

Return on Equity

-69.78%

Return on Assets

-63.07%

Free Cashflow Yield

-19.29%

NVNO Investor Care

Shares Dilution (1Y)

44.39%

Diluted EPS (TTM)

-1.2

Revenue Breakdown

As of: Jun 30, 2025
2018202020222024050K100K150K200K
Total
TotalValuePercent

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
20182019202020212022202320242025050K100K150K200K250K300K350K400K450K
Net sales
YearQ1Q2Q3Q4
20250421.0K00
2024194.0K228.0K278.0K0
2023201.0K203.0K172.0K180.0K
202220.0K54.0K122.0K161.0K
20213.0K10.0K15.0K0
2019186.7K103.4K61.7K31.2K
2018363.2K304.3K245.4K186.6K
2017000422.1K
Get all data in R, Python etc through our Historical Stock Data APIs

About enVVeno Medical Corporation

enVVeno Medical Corporation, a clinical med-tech company, focuses on the development of various bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous diseases. The company's lead product is the VenoValve, a surgical implant being developed for the treatment of chronic venous disease. Its VenoValve is implanted in the femoral vein and acts as a one-way valve to help restore proper blood flow in the leg. The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021. enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California.
 CEO
 WEBSITEenvveno.com
 SECTORHealthcare
 INDUSTRYMedical Devices
 EMPLOYEES30

enVVeno Medical Corporation Frequently Asked Questions

What is the ticker symbol for enVVeno Medical Corporation? What does NVNO stand for in stocks?

NVNO is the stock ticker symbol of enVVeno Medical Corporation. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of enVVeno Medical Corporation (NVNO)?

As of Mon Aug 18 2025, market cap of enVVeno Medical Corporation is 96.43 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of NVNO stock?

You can check NVNO's fair value in chart for subscribers.

Is enVVeno Medical Corporation a good stock to buy?

The fair value guage provides a quick view whether NVNO is over valued or under valued. Whether enVVeno Medical Corporation is cheap or expensive depends on the assumptions which impact enVVeno Medical Corporation's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for NVNO.

What is enVVeno Medical Corporation's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Aug 18 2025, NVNO's PE ratio (Price to Earnings) is -4.18 and Price to Sales (PS) ratio is 229.05. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. NVNO PE ratio will change depending on the future growth rate expectations of investors.